Compare Abbott Laboratories (ABT) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while State Street Real Estate Select Sector SPDR ETF trades at $44.14. The key difference: Abbott Laboratories pays a 2.63% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XLRE | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $45.36 |
52-Week Low | $82.57 | $40.01 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
XLRE trades at $44.29, down 0.9% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a low 0.08% expense ratio and focuses exclusively on U.S. real estate investment trusts. Recent news highlights XLRE's cost advantage over global real estate ETFs and discusses the REIT sector's resilience amid interest rate volatility.
The outlook for XLRE hinges on U.S. real estate fundamentals and interest rate trends. Opportunities include potential sector recovery and durable dividends, but risks remain from rising Treasury yields and economic uncertainty. Wall Street sentiment is mixed, with technicals suggesting near-term consolidation around key support at $44.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
